Baseline Cohort Malaria Morbidity Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

459 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-07

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The BLOOMy study is a longitudinal prospective cohort study of healthy children to assess the incidence of clinical malaria over the main transmission season. Participants will undergo baseline clinical and biological assessments then will receive a curative dose of either artesunate or dihydroartemisinin-piperaquine to clear any existing parasitemia. Clearance of parasites will be confirmed 3 weeks later by Polymerase chain reaction (PCR) and only participants with negative PCR will be definitively enrolled for the longitudinal follow up. Both active and passive case detection will be used to ensure that capture of a high proportion of infections in the cohort is achieved.

Blood samples for immunological assessments will be obtained at Day 0 of each positive blood smear episode before treatment and at Weeks 4 post treatment.

Participants will be followed for a minimum of six months throughout the malaria peak transmission season.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria

NCT00425763

Malaria

COMPLETED PHASE4

In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso

NCT00808951

Malaria

COMPLETED PHASE4

Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso

NCT05946642

Malaria

UNKNOWN PHASE3

Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in Mozambique

NCT06970600

Malaria (Uncomplicated)

COMPLETED NA

Amodiaquine+Artesunate for Uncomplicated Malaria Treatment

NCT01213433

Uncomplicated Malaria

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The BLOOMy study has two co-Primary objectives:

* To assess the incidence of clinical malaria meeting the primary case definition in children aged 1.5 to 12 years living in the study area over the main transmission season
* To assess the occurrence of reinfection following the radical cure of existing parasitemia.

The secondary objectives are:

* To assess the incidence of clinical malaria meeting various secondary cases definition in children aged 1.5 to 12 years living in the study area over the main transmission season
* To measure the immune responses (humoral and cell-mediated) to a panel of malaria vaccine candidate antigens
* To assess the molecular force of infection
* To pilot and standardize malaria morbidity assessment in three phase 2 malaria vaccine testing sites.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy children aged 1.5 to 12 years
* Residence in the study area or surroundings for the period of the study
* Written informed consent from parents/legally acceptable representatives and an assent for children

Exclusion Criteria

* Complicated symptomatic malaria (defined according to standard World Health Organization criteria)
* Anaemia (Hb\<8g/dL),
* Any (chronic) illness that requires immediate clinical care.
* Family history of sudden death or of congenital or clinical conditions known to prolong QTcB or QTcF interval or e.g. family history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or severe cardiac disease
* Any treatment which can induce a lengthening of QT interval
* Known history of hypersensitivity or allergic reactions to piperaquine or other aminoquinolones
* Receipt of any blood transfusion or immunoglobulins within 3 months
* Known history of hypersensitivity or allergic reactions to artesunate
* Severe malnutrition (weight-for-height being below -3 standard deviation or less than 70% of median of the World Health Organization (WHO) normalized reference values).
* Weight below 5 kg
* Current or previous participation in malaria vaccine trials
* Current active participation in any trial involving administration of investigational drug.

Minimum Eligible Age

18 Months

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No